Vaccine Against African Horse Sickness Virus
AssigneesMerial Limited, University of Pretoria, The Regents of the University of California
InventorsJules Maarten Minke, Jean Christophe Audonnet, Alan John Guthrie, Nigel James Maclachlan, Jiansheng Yao
Life of this patent
Estimating the term…
Abstract
The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.
Claims19
1-43. (canceled)
A vaccine composition comprising a recombinant poxvirus wherein the recombinant poxvirus comprises a nucleic acid molecule encoding an African Horse Sickness Virus (AHSV) VP2 polypeptide;
- and wherein the composition is capable of eliciting a protective immune response in an equine animal.
An expression vector comprising a polynucleotide having the sequence as set forth in SEQ ID NO:4, 28, 42 or 48;
- wherein the vector is capable of eliciting a protective immune response in an equine animal against AHSV.
An isolated African Horse Sickness Virus AHSV4-Jane strain, having a nucleic acid sequence comprising the sequence as set forth in SEQ ID NO:48.
An isolated polypeptide having the sequence as set forth in SEQ ID NO:
- 1, 30, 44 or 49.
An isolated nucleic acid having the sequence as set forth in SEQ ID NO:
- 4, 18, 28, 42 or 48.
Dependencies are inferred from the claim text.